MAZE Stock Forecast & Price Target

Maze Therapeutics is attractive because its APOL1 program, MZE829, has early human data showing about 48.6% UACR reduction in non-diabetic AMKD and no serious adverse events, while peer data from VRTX strengthened confidence that proteinuria reductions in this disease can translate into meaningful kidney outcomes. The PARASOL findings also support the company’s clinical strategy by showing that a ≥50% UPCR decline at 12 months was linked to a 68% lower kidney-failure hazard and that proteinuria response can serve as a practical surrogate for accelerated approval, potentially de-risking Maze’s ongoing HORIZON and future pivotal work. Beyond MZE829, MZE782 adds a second value driver with Phase 1 data showing a 39-fold increase in urinary Phe at 960mg and a clean safety profile, while the April registered offering lifted cash to $495M and extended runway into 2029.

Maze Therapeutics is exposed to substantial clinical and regulatory risk because its accelerated approval strategies may still require additional data, longer studies, or more restrictive labels that could weaken commercial adoption. The company also faces a difficult competitive backdrop in CKD and related CVRM diseases, where branded rivals such as VRTX and Otsuka, generic players, and additional entrants over time could pressure differentiation and limit market share. Fundamentally, the outlook remains negative because the company is likely to need additional external funding to keep advancing its platform, and any inability to access capital markets could delay or even terminate development programs.